talsaclidine fumarate

selectively activate M1 receptors in sympathetic ganglia; may be useful in cholinergic substitution therapy of Alzheimer's disease

Also Known As:

3-(2-propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; WAL 2014; WAL 2014 FU; WAL-2014; 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1)

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - talsaclidine fumarate: 4

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/1995 - "Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease." 01/01/1993 - "It is concluded that WAL 2014 due to its preferential neuronal activity is a promising candidate for a cholinergic substitution therapy in Alzheimer's disease."
2.	Contracture 07/09/1997 - "The aim of the present investigation was to determine the reasons why the muscarinic receptor agonist talsaclidine (WAL 2014 FU, 1-azabicyclo[2.2.2] octane,3-(2-propynyloxy)-, (R)-,(E)-2-butenedioate) is devoid of bronchospastic effects in anaesthetized guinea pigs but causes contracture in isolated tracheal muscle from this species. "
3.	Bronchial Spasm 08/01/1997 - "The pronounced susceptibility of WAL 2014 FU-induced contraction to functional antagonism by beta-adrenoceptor activation provides an explanation for the failure of the drug to induce bronchospasm in vivo." 08/01/1997 - "In contrast to other muscarinic agonists, WAL 2014 FU does not induce bronchospasm in laboratory animals. "

Related Drugs and Biologics

1.	Muscarinic Agonists
2.	Cholinergic Agents (Cholinergics)
3.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
4.	Adrenergic Receptors (Adrenergic Receptor)
5.	octane

Related Therapies and Procedures

1.	Therapeutics